HER2+ Metastatic Breast Cancer: What Targeted Therapy Means for Managed Care
Monday, Nov. 9, 2020, 10-11:30am ET
Provided by Pharmacy Times Continuing Education.
This activity is supported by educational grants from Seattle Genetics, Daiichi Sankyo, Inc., and AstraZeneca.
Continuing education credit available for pharmacists.
Up to 25% of breast cancers overexpress human epidermal growth factor 2 (HER2), which is a marker of aggressive disease. Determination of receptor status is critical to patient selection for therapy in breast cancer, as prognosis for untreated disease can be poor, with up to 25% of patients with early-stage HER2+ disease experiencing recurrence. Additionally, in the setting of resistant HER2+ disease, many patients will develop incurable metastatic spread. Guidelines recommend HER2-targeted therapies be used for first-line treatment in patients with a positive HER2 status, but use of these therapies carries a financial impact to multiple stakeholders. Managed care pharmacists are at the forefront of providing services to patients receiving oncology therapies, and must consider the prior authorization and documentation processes as well as cost-effectiveness to aid in the selection and management of HER2-targeted therapies for optimal patient outcomes.
Pharmacy Times Continuing Education